Management of lithium in patients with cancer.
This article reviews the management of lithium in patients who require optimum management of cancer and simultaneous prevention of mania or depression in lithium-sensitive affective illness. Two cases are described. Discussion focuses on whether lithium should be continued during chemotherapy and radiation treatment, the complications that would lead to lithium toxicity in an otherwise stable patient, the likely settings for hypothyroidism, and the role of lithium to stabilize steroid-induced affective changes. The authors conclude that lithium may be withheld 1 or 2 days before cytotoxic chemotherapy and restarted when the patient is able to drink. It may be given as usual through routine radiation treatment, but it should be discontinued during cranial radiation. Calcium, renal, cardiac, and thyroid functions should be monitored.
Greenberg
D B
DB
Department of Psychiatry and Section Hematology-Oncology, Massachusetts General Hospital Cancer Center, Boston.
Younger
J
J
Kaufman
S D
SD
D000305:Adrenal Cortex Hormones / Q000378:metabolism; D001145:Arrhythmias, Cardiac / Q000139:chemically induced; D001943:Breast Neoplasms / Q000150:complications / Q000188:drug therapy / Q000523:psychology*; D002118:Calcium / Q000097:blood / Q000378:metabolism; D003866:Depressive Disorder / Q000188:drug therapy* / Q000209:etiology*; D004358:Drug Therapy; D005260:Female; D006801:Humans; D006934:Hypercalcemia / Q000150:complications; D007037:Hypothyroidism / Q000139:chemically induced; D007674:Kidney Diseases / Q000139:chemically induced; D008094:Lithium / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D008875:Middle Aged; D011878:Radiotherapy
D000305:Adrenal Cortex Hormones; D008094:Lithium; D002118:Calcium